Industry
Drug Manufacturers - Specialty & Generic
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Loading...
Open
1.12
Mkt cap
43M
Volume
171K
High
1.16
P/E Ratio
-1.50
52-wk high
3.07
Low
1.12
Div yield
N/A
52-wk low
1.11
Portfolio Pulse from
November 06, 2024 | 9:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 12:21 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 10:37 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 12:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 29, 2024 | 3:36 am
Portfolio Pulse from Benzinga Insights
January 29, 2024 | 2:44 pm
Portfolio Pulse from Benzinga Insights
January 08, 2024 | 2:44 pm
Portfolio Pulse from Benzinga Newsdesk
January 05, 2024 | 1:37 pm
Portfolio Pulse from Benzinga Insights
January 02, 2024 | 9:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.